Sun Pharma Advanced Research Company (SPARC) Q4 24/25 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, were approved, showing continued losses but with ongoing promoter support for going concern status.

• Board approved raising up to Rs. 1,800 crores via securities issuance, subject to shareholder and regulatory approvals.

• Appointments and re-appointments of key directors and CEO, and appointment of new secretarial auditors, were approved.

Financial highlights

• Standalone revenue from operations for FY25 was Rs. 7,177 lakhs, down from Rs. 7,555 lakhs in FY24; consolidated revenue was Rs. 7,177 lakhs, down from Rs. 7,555 lakhs.

• Standalone net loss for FY25 was Rs. 34,522 lakhs, compared to Rs. 38,811 lakhs in FY24; consolidated net loss was Rs. 34,251 lakhs, compared to Rs. 38,721 lakhs.

• Total expenses decreased year-over-year, with standalone expenses at Rs. 41,878 lakhs (FY25) vs. Rs. 49,313 lakhs (FY24); consolidated expenses at Rs. 41,634 lakhs (FY25) vs. Rs. 49,185 lakhs (FY24).

• Basic and diluted EPS (standalone) for FY25 was Rs. (10.64) vs. Rs. (11.96) in FY24; consolidated EPS was Rs. (10.55) vs. Rs. (11.93).

• Cash used in operating activities (consolidated) for FY25 was Rs. (36,029) lakhs, improved from Rs. (42,920) lakhs in FY24.

Outlook and guidance

• Board approved enabling resolution to raise up to Rs. 1,800 crores to support future growth and operations, subject to approvals.

• Promoter group support letter continues to underpin going concern status despite ongoing losses.